Rising innovation barriers in China's healthcare sector, with AI drug discovery commercialization and BD as key themes

Overview

This report summarizes J.P. Morgan's two-day tour of multiple Chinese healthcare companies in Beijing and Shanghai from May 18 to 19, 2026, covering AI drug discovery (AIDD), biotechnology, and medical technology. The report argues that four major themes are emerging in the sector: AI platform commercialization is becoming more verifiable, innovation pipelines are shifting from fast-follow to differentiation, BD deals are becoming an important tool for financing and globalization, and hospitals are accelerating adoption of surgical robots and biomarker-driven oncology treatment.

Core views

The core view is that innovation barriers in China's healthcare sector are rising, but this also makes high-quality companies more globally attractive. AI drug discovery companies are no longer stuck at the concept stage; instead, they are forming clearer paths to profitability through large partnerships, platform-based revenue, and support for internal pipelines. Biotech companies are advancing pipelines around differentiated mechanisms and areas of high unmet need. Meanwhile, partnerships with global players such as AstraZeneca, BMS, and Pfizer Ventures can extend cash runways and reduce the risk of independently bearing global clinical trial costs.

Analysis framework

Based on company visits, management discussions, selected expert interviews, and company-disclosed data, the report analyzes China's healthcare sector across four dimensions: AIDD commercialization, innovation pipeline quality, BD financing structures, and hospital adoption of technology.

Methodology notes

• field researchtwo-day healthcare company tour

  Observe industry trends through company visits in Beijing and Shanghai

  The tour covered AIDD, biotech, and medtech companies, using management commentary and case studies to validate the industry's shift from concept to commercialization.

• industry trend analysisAI drug discovery commercialization framework

  Assess commercialization maturity through AI models, AI agents, partnership value, and revenue visibility

  The report uses XtalPi, Harbour BioMed/Nona Biosciences, METiS, and Deep Intelligent Pharma as case studies to evaluate whether AI tools have entered real R&D workflows and are generating revenue.

• innovation quality assessmentdifferentiated pipelines and mechanism innovation

  Assess pipeline quality based on targets, MoA, clinical stage, and data catalysts

  The report emphasizes that companies such as Sirius Therapeutics, GluBio, and InnoCare are not merely pursuing fast-follow strategies, but are instead positioning in differentiated areas such as Factor XI siRNA, molecular glues, BCL-2, and TYK2/TYK2-JAK1/IL-17.

• business model analysisBD and global partnership financing framework

  Ease financing pressure through license-out deals, global partnerships, and NewCo structures

  The report argues that BD is becoming a standard capability for Chinese biotech companies, helping them secure external funding, access global resources, and preserve cash runway.

• end-demand validationhospital advanced technology adoption framework

  Assess hospital demand through installations, remote surgery, NGS, and targeted therapy adoption

  MicroPort MedBot's robot installation guidance and remote surgery cases, along with oncologists' use of NGS and targeted therapies, support recognition of ROI for advanced technologies at the hospital level.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• China healthcare sector

  The sector as a whole benefits from innovation upgrading and global collaboration

  Strengths

  AI commercialization, differentiated pipelines, BD financing, and hospital technology adoption create multiple growth drivers.

  Weaknesses

  The sector remains highly dependent on clinical success, financing conditions, and hospital budgets.

  Comparison

  Compared with the past fast-follow model, the report emphasizes deeper innovation and verifiable commercialization.

  Risks

  If AI revenue proves unsustainable, BD deals are delayed, or clinical data disappoints, sector re-rating could be hindered.

• XtalPi (2228.HK, NC)

  Representative AIDD commercialization company

  Strengths

  Covers modalities such as multispecific antibodies, peptides, and siRNA, with hundreds of AI models, 10,000+ AI agents, and a US$345 million partnership with Eli Lilly.

  Weaknesses

  The report does not provide details on earnings quality, revenue recognition timing, or long-term customer concentration.

  Comparison

  Compared with concept-stage AI platforms, the XtalPi case is more oriented toward verifiable commercialization.

  Risks

  Execution of partnerships, sustainability of platform revenue, and conversion of drug discovery outcomes still need to be validated.

• Harbour BioMed / Nona Biosciences (2142.HK, NC)

  A case of a traditional biotech adopting an AI-native discovery engine

  Strengths

  Nona Biosciences uses AI for preclinical screening and internal pipeline generation, and gains option-fee economics through pre-clinical out-licensing with AstraZeneca, BMS, and others.

  Weaknesses

  Dependent on the pace of partnership deals and the conversion efficiency of preclinical assets.

  Comparison

  Compared with pure AI platforms, the company is more of a model that embeds AI into antibody discovery and BD.

  Risks

  If data for CLDN18.2xCD3 TCE and long-acting TSLP mAb fall short of expectations, BD value may decline.

• METiS (7666.HK, NC)

  A case combining AI with mRNA drugs and delivery platforms

  Strengths

  Advances internal mRNA assets, improves delivery, and seeks out-licensing through the AiLNP, AiRNA, and AiTEM platforms.

  Weaknesses

  As a newly listed company, commercialization and platform validation may still take a relatively long time.

  Comparison

  Compared with XtalPi, it is more focused on mRNA drugs and delivery technologies.

  Risks

  There is uncertainty around clinical translation of mRNA assets, delivery safety, and repeatability of licensing transactions.

• Sirius Therapeutics (private)

  A differentiated siRNA pipeline case

  Strengths

  SRSD107 showed 90%-95% Factor XI knockdown and is planned to move into Ph3 trials, entering a direction pursued by relatively few siRNA companies.

  Weaknesses

  As a private company, disclosure is limited, and subsequent clinical design and commercialization pathways remain unclear.

  Comparison

  The report views it as a differentiated pipeline rather than a simple fast-follow strategy.

  Risks

  Ph3 trial success rate, long-term safety, and the competitive landscape remain key uncertainties.

• GluBio (private)

  A case of novel molecular glues and differentiated MoA

  Strengths

  Advancing novel molecular glues such as GLB-005 and GLB-007, targeting indications including sickle cell disease and beta thalassemia.

  Weaknesses

  Early-stage innovative mechanisms typically require long validation cycles and carry high clinical risk.

  Comparison

  Compared with conventional antibody or small-molecule fast-follow strategies, the molecular glue direction places more emphasis on novel mechanisms.

  Risks

  Mechanism validation, toxicity, indication selection, and financing capability may all affect value realization.

• InnoCare (9969.HK, NC)

  A pipeline company in hematologic oncology and autoimmune disease

  Strengths

  1Q26 revenue growth of 38.65%, with the BCL-2 inhibitor advancing in both monotherapy and combination trials in hematologic oncology, while TYK2, TYK2/JAK1, and IL-17 oral inhibitors will have key data catalysts.

  Weaknesses

  Multiple pipelines still require further clinical data validation, and the competitive landscape is crowded.

  Comparison

  The report presents it as a biotech case balancing revenue growth and upcoming data catalysts.

  Risks

  Clinical data, safety, indication expansion, and commercial competition are the main risks.

• Syneron (private)

  A BD case using global partnerships to reduce financing pressure

  Strengths

  Has completed a global R&D collaboration with AstraZeneca and received support from AstraZeneca and Pfizer Ventures, with an annualized R&D burn rate of US$60-70 million.

  Weaknesses

  Commercialization of macrocyclic peptide therapies still requires long-term clinical validation.

  Comparison

  Compared with independently bearing global trials, the company preserves cash runway through its BD structure.

  Risks

  Changes in partner priorities, milestone realization, and clinical failure could affect funding and valuation.

• MicroPort MedBot (2252.HK, OW)

  A representative of accelerating hospital adoption of surgical robots

  Strengths

  Reiterated guidance for 200 new robot installations in 2026, and the Toumai Remote system has completed 800+ remote surgeries, reflecting hospital recognition of the platform's ROI.

  Weaknesses

  Conversion of installations into recurring revenue, consumables revenue, and profitability still needs to be tracked.

  Comparison

  Compared with early proof-of-concept stages, the report emphasizes end-market adoption evidence from remote surgery and installation data.

  Risks

  Hospital capital expenditure, competition, regulation, physician training, and insufficient utilization may affect growth.

• AK112, TROP2 ADC, and biomarker-driven oncology treatment

  A beneficiary direction of the precision oncology trend

  Strengths

  Real-world oncology treatment increasingly relies on NGS panels, targeted therapies, and precise patient selection.

  Weaknesses

  Clinicians remain concerned about safety in 1L treatment, and response rate alone is no longer sufficient.

  Comparison

  Compared with focusing only on response rate, the report emphasizes survival data, patient selection, and treatment sequencing.

  Risks

  Safety, OS/PFS data, patient stratification, and insufficient evidence on treatment sequencing may limit adoption.

Key data

• Tour dates2026-05-18 to 2026-05-19J.P. Morgan visited multiple healthcare companies in Beijing and Shanghai.
• XtalPi partnership valueUS$345 millionXtalPi signed a major partnership with Eli Lilly in November 2025, which the report views as validation of AIDD commercialization.
• XtalPi platform scaleHundreds of AI models, 10,000+ AI agentsThe company has expanded its discovery engine to key drug modalities including multispecific antibodies, peptides, and siRNA.
• Deep Intelligent Pharma profitability1Q26 net profit exceeded full-year 2025 profitThe company uses LLMs and multi-agent systems to drive its clinical CRO business.
• Sirius Therapeutics dataSRSD107 achieved 90%-95% Factor XI knockdownThe company plans to advance SRSD107 into Ph3 trials, reflecting a differentiated siRNA strategy.
• InnoCare revenue growth1Q26 revenue grew 38.65% YoYManagement believes the company is well positioned in hematologic oncology and autoimmune diseases.
• Syneron R&D spendingAnnualized R&D burn rate of US$60-70 millionThe company maintains relatively efficient R&D investment through its AstraZeneca partnership and support from Pfizer Ventures.
• MicroPort MedBot installation guidance200 new robot installations in 2026Management reiterated this guidance, and the report believes hospitals are recognizing the platform's ROI.
• MicroPort MedBot remote surgeries800+ remote surgeriesThe Toumai Remote system demonstrates remote application scenarios for surgical robots.
• MicroPort MedBot price and rating2252.HK / HK$27.30 / OWPrice as of the close on 2026-05-22; rating is Overweight.

Impact & implications

If the trends described in the report continue, investment focus in China's healthcare sector will shift from pure R&D speed toward verifiable commercialization, differentiated innovation, global BD execution, and real hospital adoption. Potential beneficiaries may include companies with platform revenue, clinical data catalysts, global partners, and quantifiable hospital installation/usage data; however, valuations will also become more dependent on subsequent orders, clinical data, regulatory progress, and safety validation.

Risks

• The sustainability of AI drug discovery platform revenue, order conversion, and drug translation rates still needs to be validated.
• BD transactions may be affected by global pharma budgets, risk appetite, and clinical data quality, and deal pacing cannot be linearly extrapolated.
• Chinese biotech companies still face pressure from clinical failure, regulatory review, financing conditions, and cash runway.
• Hospital adoption of surgical robots and advanced diagnostic and treatment technologies depends on budgets, ROI, physician training, installation utilization, and the reimbursement environment.
• First-line oncology treatment in particular still requires safety validation, and experts explicitly remain focused on 1L drug safety.
• The report includes multiple not-covered or private companies with limited public financial data, constraining investment operability and valuation comparability.

What to watch

• Execution progress of XtalPi's partnership with Eli Lilly, revenue recognition timing, and repeatability of subsequent large partnerships.
• Harbour BioMed's global Ph1 data for CLDN18.2xCD3 TCE and Ph1 data for long-acting TSLP mAb.
• Key data catalysts for InnoCare's TYK2, TYK2/JAK1, and IL-17 oral inhibitors.
• Initiation, design, and Factor XI safety data of Sirius Therapeutics' SRSD107 Ph3 trial.
• Progress on MicroPort MedBot's 200 new robot installations in 2026, number of remote surgeries, and commercialization conversion.
• Real-world survival data, safety, and patient selection evidence for precision oncology treatments such as NGS panels, AK112, and TROP2 ADC.